Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 2 · 50%High 1 · 25%

SGLT2 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3086 participants
Low

SGLT2 inhibitors vs placebo

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Moderate

SGLT2 inhibitors vs placebo

Hypoglycaemia requiring third‐party assistance median · people with diabetes and CKD

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower hypoglycaemia requiring third‐party assistance median compared with placebo (high certainty).

1 finding from 1 review

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes only
RR 0.75 [0.65, 0.88]
14 studies · 26478 participants
High

SGLT2i vs placebo

Hypoglycaemia · CVD (ASCVD, HF, or both)

SGLT2i showed no clear difference in hypoglycaemia compared with placebo (moderate certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes only
OR 0.9 [0.75, 1.07]
4 studies · 21232 participants
Moderate